Neurogene’s (NGNE) Surprising Setback: What’s Behind the Stock Drop?
When looking at Neurogene’s stock performance year-to-date, it’s hard to ignore the impressive +269.09% increase. However, this recent downturn suggests that the market is responding to something beyond the clinical data, such as investor sentiment or broader market factors.
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene (NGNE – Research Report) and keeping the price target at ...
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side ...
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...
Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant ...
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback